Results 31 to 40 of about 4,432 (206)

Analyse des vorläufigen Berichtsplans des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen für eine Kosten-Nutzen-Bewertung zu Clopidogrel bei der peripheren arteriellen Verschlusskrankheit und beim akuten Koronarsyndrom [PDF]

, 2010
--
Aidelsburger, Pamela, Wasem, Jürgen
core   +3 more sources

HTA und aktuelle Herausforderungen: Harmonisierung, Real World Data und Surrogatparameter

GMS Medizinische Informatik, Biometrie und Epidemiologie, 2018
Health Technology Assessment is one of the standard instruments in support of the decision-making to define the public health services both internationally and in the German health care system.
Rüther, Alric, Herrmann, Kirsten H., Hebborn, Ansgar, Perleth, Matthias, Schwarzer, Ruth, Schürmann, Christoph, Sieben, Wiebke, Gillhaus, Johanna, Goertz, Ralf, Jeratsch, Ulli, Leverkus, Friedhelm, Schramm, Wendelin   +11 more
doaj   +1 more source

Institute for Quality and Efficiency in Health Care: Germany [PDF]

, 2009
Provides an overview of evidence-based policy making in the German healthcare system. Focuses on the Institute for Quality and Efficiency in Health Care, which evaluates comparative effectiveness of drugs and medical services for decisions on ...
Mona Nasser, Peter Sawicki
core  

Negative pressure wound therapy: Potential publication bias caused by lack of access to unpublished study results data [PDF]

, 2008
Background Negative pressure wound therapy (NPWT) is widely applied, although the evidence base is weak. Previous reviews on medical interventions have shown that conclusions based on published data alone may no longer hold after consideration of ...
Frank Peinemann, Natalie McGauran, Stefan Sauerland, Stefan Lange, ID Graham, E Kaltenthaler, S Wu, A Persoon, LC Argenta, S Gregor, DJ Samson, Ontario Health Technology Advisory Committee (OHTAC), CJ Whittington, S Hopewell, L McAuley, P Jüni, MT Eginton, E Moisidis, E Joseph, CM Moues, A Braakenburg, DG Armstrong, JD Vuerstaek, MB Wanner, S Llanos, TST Adams, J Fryer, M McCarthy, P Walker, CN Ford, L Bayer, SE Greer, DP Orgill, JP Stannard, DG Armstrong, J McCarthy, JA Molnar, JA Niezgoda, JP Stannard, JP Stannard, LSS Foo, SC Gupta, JC Lantis, K Dickersin, ET Crumley, S Hopewell, RJ McManus, RW Scherer, TP Klassen, F Song, JM Stern, JP Ioannidis, PJ Easterbrook, DJ Cook, Y Dundar, L Hartling, D Moher, P McCulloch, D Moher, SS Buchkowsky, H Melander, J Lexchin, JE Bekelman, AW Jorgensen, V Costa, CT Pham, SK McCallon, DG Genecov, Ontario Health Technology Advisory Committee (OHTAC), C Pham, JDD Vuerstaek, MC Obdeijn, W Payne, CM Moues, T Heath, E Joseph, JP Stannard, K Buttenschön, MG Jeschke, D Evans, A Fisher, S Higgins   +81 more
core   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source

Höchstmöglicher ESMO-Wert vs. kein Zusatzznutzen

Monitor Versorgungsforschung
Im Titelinterview mit „Monitor Versorgungsforschung“ (02/25) ging Dr. med. Thomas Kaiser, Institutsleiter des IQWiG, kurz auf die Nutzenbewertung des Wirkstoffs Pembrolizumab und des MSD-Arznemittels „Keytruda“ ein (1): Auf die Frage „Wie kommt es, dass ...
Peter Stegmaier
doaj   +1 more source

Study filters for non-randomized studies of interventions consistently lacked sensitivity upon external validation

BMC Medical Research Methodology, 2018
Background Little evidence is available on searches for non-randomized studies (NRS) in bibliographic databases within the framework of systematic reviews.
Elke Hausner, Maria-Inti Metzendorf, Bernd Richter, Fabian Lotz, Siw Waffenschmidt   +4 more
doaj   +1 more source

Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG

BMC Health Services Research, 2020
Background The question of how to set the cost-effectiveness threshold for new, innovative medicines is a matter of ongoing controversy. One prominent proposal suggests that the cost-effectiveness threshold adopted by the U.K.
Afschin Gandjour
doaj   +1 more source

Policy Networks and Policy Entrepreneurship in the EU: Explaining Structural Policy Change in Pharmaceutical Innovation Incentives and Health Technology Assessment

European Policy Analysis, EarlyView.
ABSTRACT Policy process research has excelled in explaining structural policy change within national settings, but extensions and applications to the EU level have long proven challenging for scholars. Given that the EU is currently experiencing its longest period of Treaty stability since the 1980s—having evolved into a sui generis political system ...
Vassilis Karokis‐Mavrikos
wiley   +1 more source

Anwendungsbegleitende Datenerhebungen für die Nutzenbewertung von Arzneimitteln in Deutschland: Warum, wann und wie?

GMS Medizinische Informatik, Biometrie und Epidemiologie
For newly authorised medicinal products with new active substances, a benefit assessment is carried out at the time of their market access in Germany. The subject of this assessment is the question of the additional benefit of the new active substance ...
Kaiser, Thomas, Vervölgy, Volker
doaj   +1 more source